151 related articles for article (PubMed ID: 16135730)
1. Cost-effectiveness of isoniazid chemoprevention in close contacts.
Diel R; Nienhaus A; Schaberg T
Eur Respir J; 2005 Sep; 26(3):465-73. PubMed ID: 16135730
[TBL] [Abstract][Full Text] [Related]
2. [Cost effectiveness analysis of isoniazid preventive therapy to the contacts of tuberculosis patients under Japanese settings].
Yoshiyama T
Kekkaku; 2000 Nov; 75(11):629-41. PubMed ID: 11140086
[TBL] [Abstract][Full Text] [Related]
3. A quantitative benefit-risk analysis of isoniazid for treatment of latent tuberculosis infection using incremental benefit framework.
Sadatsafavi M; Marra C; Marra F; Moran O; FitzGerald JM; Lynd L
Value Health; 2013; 16(1):66-75. PubMed ID: 23337217
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness of interferon-gamma release assay testing for the treatment of latent tuberculosis.
Diel R; Wrighton-Smith P; Zellweger JP
Eur Respir J; 2007 Aug; 30(2):321-32. PubMed ID: 17504793
[TBL] [Abstract][Full Text] [Related]
5. Modelling the cost-effectiveness of strategies to prevent tuberculosis in child contacts in a high-burden setting.
Mandalakas AM; Hesseling AC; Gie RP; Schaaf HS; Marais BJ; Sinanovic E
Thorax; 2013 Mar; 68(3):247-55. PubMed ID: 22717944
[TBL] [Abstract][Full Text] [Related]
6. Enhanced cost-benefit analysis of strategies for LTBI screening and INH chemoprevention in Germany.
Diel R; Schaberg T; Loddenkemper R; Welte T; Nienhaus A
Respir Med; 2009 Dec; 103(12):1838-53. PubMed ID: 19682884
[TBL] [Abstract][Full Text] [Related]
7. Monitored isoniazid prophylaxis for low-risk tuberculin reactors older than 35 years of age: a risk-benefit and cost-effectiveness analysis.
Salpeter SR; Sanders GD; Salpeter EE; Owens DK
Ann Intern Med; 1997 Dec; 127(12):1051-61. PubMed ID: 9412307
[TBL] [Abstract][Full Text] [Related]
8. Isoniazid preventive therapy programmes for healthcare workers in India: translating evidence into policy.
Raj R; Prasad H; Arya BK; Bhattacharya SD
Natl Med J India; 2011; 24(4):201-7. PubMed ID: 22208138
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness of LTBI treatment for TB contacts in British Columbia.
Tan MC; Marra CA; Sadatsafavi M; Marra F; Morán-Mendoza O; Moadebi S; Elwood RK; FitzGerald JM
Value Health; 2008; 11(5):842-52. PubMed ID: 18489519
[TBL] [Abstract][Full Text] [Related]
10. Costs and cost-effectiveness of adolescent compliance with treatment for latent tuberculosis infection: results from a randomized trial.
Kominski GF; Varon SF; Morisky DE; Malotte CK; Ebin VJ; Coly A; Chiao C
J Adolesc Health; 2007 Jan; 40(1):61-8. PubMed ID: 17185207
[TBL] [Abstract][Full Text] [Related]
11. Short-course rifampin and pyrazinamide compared with isoniazid for latent tuberculosis infection: a cost-effectiveness analysis based on a multicenter clinical trial.
Jasmer RM; Snyder DC; Saukkonen JJ; Hopewell PC; Bernardo J; King MD; Kawamura LM; Daley CL;
Clin Infect Dis; 2004 Feb; 38(3):363-9. PubMed ID: 14727206
[TBL] [Abstract][Full Text] [Related]
12. Cost-Effectiveness of isoniazid preventive therapy among HIV-infected patients clinicaly screened for latent tuberculosis infection in Dar es Salaam, Tanzania: A prospective Cohort study.
Shayo GA; Chitama D; Moshiro C; Aboud S; Bakari M; Mugusi F
BMC Public Health; 2017 Jul; 18(1):35. PubMed ID: 28724374
[TBL] [Abstract][Full Text] [Related]
13. Risk of tuberculosis among contacts of isoniazid-resistant and isoniazid-susceptible cases.
Tuberculosis Research Centre, Indian Council of Medical Research (ICMR), Chennai, India
Int J Tuberc Lung Dis; 2011 Jun; 15(6):782-8. PubMed ID: 21575299
[TBL] [Abstract][Full Text] [Related]
14. The cost-effectiveness of preventing tuberculosis in physicians using tuberculin skin testing or a hypothetical vaccine.
Nettleman MD; Geerdes H; Roy MC
Arch Intern Med; 1997 May; 157(10):1121-7. PubMed ID: 9164378
[TBL] [Abstract][Full Text] [Related]
15. Tuberculosis vaccination versus isoniazid preventive therapy: a decision analysis to determine the preferred strategy of tuberculosis prevention in HIV-infected adults in the developing world.
Sterling TR; Brehm WT; Moore RD; Chaisson RE
Int J Tuberc Lung Dis; 1999 Mar; 3(3):248-54. PubMed ID: 10094327
[TBL] [Abstract][Full Text] [Related]
16. Potential cost-effectiveness of rifampin vs. isoniazid for latent tuberculosis: implications for future clinical trials.
Esfahani K; Aspler A; Menzies D; Schwartzman K
Int J Tuberc Lung Dis; 2011 Oct; 15(10):1340-6. PubMed ID: 22283892
[TBL] [Abstract][Full Text] [Related]
17. Is isoniazid for 6 months more cost-effective than isoniazid for 9 months?
Pina JM; Clotet L; Sala MR; Ferrer A; Arias C; Domínguez A
Int J Tuberc Lung Dis; 2012 Jun; 16(6):768-73. PubMed ID: 22508169
[TBL] [Abstract][Full Text] [Related]
18. The cost-effectiveness of evidence-based guidelines and practice for screening and prevention of tuberculosis.
Macintyre CR; Plant AJ; Hendrie D
Health Econ; 2000 Jul; 9(5):411-21. PubMed ID: 10903541
[TBL] [Abstract][Full Text] [Related]
19. Effectiveness and cost effectiveness of early and late prevention of HIV/AIDS progression with antiretrovirals or antibiotics in Southern African adults.
Bachmann MO
AIDS Care; 2006 Feb; 18(2):109-20. PubMed ID: 16338768
[TBL] [Abstract][Full Text] [Related]
20. Cost-effectiveness of tuberculosis screening and observed preventive therapy for active drug injectors at a syringe-exchange program.
Perlman DC; Gourevitch MN; Trinh C; Salomon N; Horn L; Des Jarlais DC
J Urban Health; 2001 Sep; 78(3):550-67. PubMed ID: 11564856
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
